HeartBeam

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

HeartBeam reports Q1 loss, eyes FDA clearances for growth

HeartBeam's Q1 2024 performance showed financial challenges but promising technological advancements
The company's focus on FDA clearances and AI development positions it for growth
Opportunities in remote cardiac monitoring and AI-driven healthcare present avenues for expansion
Balancing financial stability with innovation will be key for HeartBeam's future success

HeartBeam advances AIMIGo technology despite financial challenges

HeartBeam is making progress towards FDA clearance for its innovative cardiac monitoring device, AIMIGo.
Despite financial challenges, the company's strong IP protection and AI capabilities position it well for future growth.
Opportunities lie in expanding technology applications, gaining regulatory approval, and leveraging AI for automated diagnostics.

HeartBeam reports Q3 loss, progresses FDA review, and strengthens leadership

HeartBeam's Q3 2024 financials show a net loss of $4.979 million, with a focus on managing cash burn and aligning capital raising with milestones.
The company's core technology and clinical evidence position it well for FDA clearances and commercial launch preparations.
New management appointments bring leadership strength to drive HeartBeam's growth and innovation in cardiac care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.

BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?

Bull of the Day: BioTelemetry (BEAT)

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTelemetry (BEAT) Earnings Expected to Grow: Should You Buy?

Healthcare services is the future for Apple as well as for BioTelemetry in its latest acquisitions of Geneva and LifeWatch.

BioTelemetry & Apple have teamed up as partners in Apple's Heart study

Is  (BEAT) Outperforming Other Medical Stocks This Year?

Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year?

In the latest trading session, BioTelemetry (BEAT) closed at $60.03, marking a -0.94% move from the previous day.

BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know

BioTelemetry (BEAT) closed the most recent trading day at $68.46, moving +0.87% from the previous trading session.

BioTelemetry (BEAT) Gains But Lags Market: What You Should Know

News for HeartBeam Stock (BEAT)